Evidence map›Paper›PMID 36527378›Full record

ArticleSeminars in ophthalmology2023

Penetrating Keratoplasty: Indications and Graft Survival by Geographic Region.

Sana Qureshi, Thomas H Dohlman

Open access · greenAbstract read
In one paragraph

Article in Seminars in ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Corneal Myofibroblasts Suppress T-Cell Immunity in Corneal Transplantation.Investigative ophthalmology & visual science · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Main issues in penetrating keratoplasty.Taiwan journal of ophthalmology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sana QureshiCornea Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
Thomas H DohlmanCornea Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-3818-4541
Massachusetts Eye and Ear Infirmary · US

Funding

The Fibrosis-Immunity Interface in Corneal TransplantationK08EY031759 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI DOHLMAN, THOMAS · 2020 to 2024
$1.2M
NEI NIH HHS K08 EY031759
6 · The paper itself

Abstract

Corneal transplantation, or penetrating keratoplasty (PK), is the most common form of solid-organ transplantation performed worldwide. Here, we evaluated the indications for PK and rates of transplant survival around the world by geographic region. We conducted a literature search of PubMed, MEDLINE, and Google Scholar databases and identified 155 relevant studies from 41 countries published between 1987 and 2021. The most common indications for PK were keratoconus in Europe, Africa, the Middle East, Australia, New Zealand, and Central and South America, bullous keratopathy in North America, and corneal scarring in Asia. The overall global mean graft survival rates at 1-, 2-, 3-, 5-, and 10-years were 88.6%, 81.2%, 78.9%, 72.8%, and 61.2%, respectively. Through this systematic analysis of PK by region, we hope to bring a new perspective to the corneal transplantation literature and to potentially highlight global differences and unmet needs in patient care.

Indexed as

Corneal DiseasesCorneal TransplantationKeratoconusGraft SurvivalHumansKeratoplasty, PenetratingRetrospective StudiesVisual AcuityCorneal transplantationglobalgraft survivalindicationpenetrating keratoplastysystematic review

Identifiers

PMID36527378
PMCPMC10084850
OpenAlexW4311824500

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.